Bal Pharma Ltd's Q4FY25 Quarter Results
- 30 May 2025
Result Summary
- Bal Pharma Ltd reported a 31.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 17.5%.
- Its expenses for the quarter were up by 24.9% QoQ and 13.8% YoY.
- The net profit increased 963.5% QoQ and increased 241.4% YoY.
- The earnings per share (EPS) of Bal Pharma Ltd stood at 3.7 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 97.08 | 73.66 | 82.64 | 31.8% | 17.5% |
Total Expenses | 91.33 | 73.10 | 80.23 | 24.9% | 13.8% |
Profit Before Tax | 5.75 | 0.57 | 2.41 | 908.8% | 138.6% |
Tax | 0.22 | 0.05 | 0.79 | 340.0% | -72.2% |
Profit After Tax | 5.53 | 0.52 | 1.62 | 963.5% | 241.4% |
Earnings Per Share | 3.70 | 0.30 | 1.00 | 1133.3% | 270.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Bal Pharma Ltd is a company involved in the pharmaceutical industry, primarily engaged in the manufacturing and sale of pharmaceutical products. The company offers a range of products that typically include generic formulations, active pharmaceutical ingredients (APIs), and other related products. Bal Pharma Ltd operates within a highly competitive industry characterized by ongoing research and development and stringent regulatory requirements. Recent major developments pertaining to Bal Pharma Ltd are not available based on the given data. Without additional data, specific strategic initiatives or market expansions cannot be identified.
Revenue
For the quarter Q4FY25, Bal Pharma Ltd reported a total income of ₹97.08 crores, which represents a quarter-over-quarter (QoQ) increase of 31.8% from Q3FY25, where the total income was ₹73.66 crores. Compared to the same quarter in the previous fiscal year, Q4FY24, the total income showed a year-over-year (YoY) increase of 17.5%, with the previous figure being ₹82.64 crores. These figures reflect the company's revenue performance over the specified periods, highlighting the changes in income generation.
Profitability
The profit before tax for Q4FY25 was ₹5.75 crores, marking a significant QoQ rise of 908.8% from Q3FY25, which recorded a profit before tax of ₹0.57 crores. On a YoY basis, the increase is 138.6% from Q4FY24's profit before tax of ₹2.41 crores. The tax for Q4FY25 was ₹0.22 crores, showing a QoQ increase of 340.0% from ₹0.05 crores in Q3FY25 and a YoY decrease of 72.2% from ₹0.79 crores in Q4FY24. The profit after tax for Q4FY25 was ₹5.53 crores, representing a QoQ increase of 963.5% from Q3FY25's ₹0.52 crores, and a YoY increase of 241.4% from Q4FY24's ₹1.62 crores. Earnings per share for Q4FY25 were ₹3.70, a notable increase both QoQ by 1133.3% from ₹0.30 in Q3FY25 and YoY by 270.0% from ₹1.00 in Q4FY24.
Operating Metrics
Total expenses for Q4FY25 were ₹91.33 crores, which is a 24.9% increase QoQ from ₹73.10 crores in Q3FY25 and a 13.8% increase YoY from ₹80.23 crores in Q4FY24. These figures indicate the company's cost structure and management of operational expenses. The company's ability to generate profit and manage expenses relative to its income is reflected in these metrics. The provided data does not include specific operating ratios such as the P/E ratio, debt-to-equity ratio, or current ratio, thus they cannot be calculated from the given information. These metrics are vital for a comprehensive understanding of the company's operational efficiency and financial health.